0001179110-20-002261.txt : 20200225
0001179110-20-002261.hdr.sgml : 20200225
20200225171021
ACCESSION NUMBER: 0001179110-20-002261
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200221
FILED AS OF DATE: 20200225
DATE AS OF CHANGE: 20200225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scoggins Christopher J
CENTRAL INDEX KEY: 0001772286
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-02189
FILM NUMBER: 20651996
MAIL ADDRESS:
STREET 1: 100 ABBOTT PARK ROAD
CITY: ABBOTT PARK
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ABBOTT LABORATORIES
CENTRAL INDEX KEY: 0000001800
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 360698440
STATE OF INCORPORATION: IL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 ABBOTT PARK ROAD
CITY: ABBOTT PARK
STATE: IL
ZIP: 60064-3500
BUSINESS PHONE: 2246676100
MAIL ADDRESS:
STREET 1: 100 ABBOTT PARK ROAD
CITY: ABBOTT PARK
STATE: IL
ZIP: 60064-3500
4
1
edgar.xml
FORM 4 -
X0306
4
2020-02-21
0
0000001800
ABBOTT LABORATORIES
ABT
0001772286
Scoggins Christopher J
100 ABBOTT PARK ROAD
ABBOTT PARK
IL
60064
0
1
0
0
Senior Vice President
Common shares without par value
2020-02-21
4
A
0
11250
0
A
44828
D
Option (right to buy)
87.72
2020-02-21
4
A
0
68578
0
A
2021-02-21
2030-02-20
Common shares
68578
68578
D
These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,859 on February 21, 2021, 22,859 on February 21, 2022, and 22,860 on February 21, 2023.
Jessica H. Paik, by power of attorney for Christopher J. Scoggins
2020-02-25